|
注：董事持股数取自最新公司公告
姓名
性别
职位
年龄
薪酬
持股数(万股)
截止日期
男
Executive Director, Chief Executive Officer and Chief Scientific Officer
67
224.96万美元
未持股
2025-03-20
女
Non-executive Director and Company Secretary
73
32.43万美元
未持股
2025-03-20
男
Senior Independent Non-executive Director
64
11.70万美元
未持股
2025-03-20
男
Non-executive Director and Chairman
71
8.13万美元
未持股
2025-03-20
女
Non-executive Director
45
未披露
未持股
2025-03-20
女
Independent Non-executive Director
66
5.91万美元
未持股
2025-03-20
男
Executive Director and Chief Financial Officer
58
100.03万美元
未持股
2025-03-20
男
Senior and Lead Independent Non-executive Director
64
11.59万美元
未持股
2025-03-20
男
Independent Non-executive Director
74
11.10万美元
未持股
2025-03-20
女
Independent Non-executive Director
58
0.94万美元
未持股
2025-03-20
男
Independent Non-executive Director
68
未披露
未持股
2025-03-20
高管介绍
注：高管持股数取自最新公司公告
姓名
性别
职位
年龄
薪酬
持股数(万股)
截止日期
男
Executive Director, Chief Executive Officer and Chief Scientific Officer
67
224.96万美元
未持股
2025-03-20
男
Senior Vice President, Corporate Management and Communications
47
未披露
未持股
2025-03-20
女
Executive Vice President, Business Development & Strategic Alliances
61
未披露
未持股
2025-03-20
男
Executive Vice President, Pharmaceutical Sciences and Manufacturing
65
未披露
未持股
2025-03-20
女
Non-executive Director and Company Secretary
73
32.43万美元
未持股
2025-03-20
男
Executive Vice President, Head of R&D and Chief Medical Officer
59
未披露
未持股
2025-03-20
男
Executive Director and Chief Financial Officer
58
100.03万美元
未持股
2025-03-20
男
Group General Counsel
55
未披露
未持股
2025-03-20
董事简历
中英对照 |
中文 |
英文
苏慰国
苏慰国先生，博士，自2017年3月起担任和黄医药（中国）有限公司执行董事及自2012年4月起担任和黄医药（中国）有限公司执行副总裁兼首席科学官。他亦为技术委员会成员。自加入公司以来，苏博士带领进行所有药物的发现及研究，包括作为肿瘤╱免疫业务的关键领导人策划科学策略，亦负责发掘公司管线中的每一种小分子候选药物。于2005年3月加入集团前，苏博士于辉瑞公司美国研发部门工作。于2017年3月，他获中国医药创新促进会（PhIRDA）授予《最具影响力的药物研发领军人物》奖。苏博士于1982年1月在上海复旦大学取得化学理学学士学位，及在哈佛大学师从诺贝尔奖得主E.J.Corey教授，在其指导下于1988年6月取得化学博士学位并从事博士后研究。2022年3月3日担任和黄医药（中国）有限公司首席执行官。于2017年3月1日获委任为和黄医药（中国）有限公司技术委员会委员。
Weiguo SU,has been an executive director of Hutchison China Meditech Limited since 2017 and chief executive officer of Hutchison China Meditech Limited Company since 2022. He is also Hutchmed (China) Limited chief scientific officer since 2012. He is a member of Hutchmed (China) Limited technical committee. Dr. Su has headed all drug discovery and research since he joined Hutchmed (China) Limited company, including master-minding Hutchmed (China) Limited scientific strategy, being a key leader of Hutchmed (China) Limited Oncology/Immunology operations, and responsible for the discovery of each and every small molecule drug candidate in Hutchmed (China) Limited pipeline. Prior to joining Hutchmed (China) Limited in 2005, Dr. Su worked with the U.S. research and development department of Pfizer, Inc. In 2017, Dr. Su was granted the prestigious award by the China Pharmaceutical Innovation and Research Development Association (PhIRDA) as one of the Most Influential Drug R&D Leaders in China. Dr. Su received a bachelor of science degree in chemistry from Fudan University in Shanghai and completed a PhD and post-doctoral fellowship in chemistry at Harvard University under the guidance of Nobel Laureate Professor E. J. Corey.
苏慰国先生，博士，自2017年3月起担任和黄医药（中国）有限公司执行董事及自2012年4月起担任和黄医药（中国）有限公司执行副总裁兼首席科学官。他亦为技术委员会成员。自加入公司以来，苏博士带领进行所有药物的发现及研究，包括作为肿瘤╱免疫业务的关键领导人策划科学策略，亦负责发掘公司管线中的每一种小分子候选药物。于2005年3月加入集团前，苏博士于辉瑞公司美国研发部门工作。于2017年3月，他获中国医药创新促进会（PhIRDA）授予《最具影响力的药物研发领军人物》奖。苏博士于1982年1月在上海复旦大学取得化学理学学士学位，及在哈佛大学师从诺贝尔奖得主E.J.Corey教授，在其指导下于1988年6月取得化学博士学位并从事博士后研究。2022年3月3日担任和黄医药（中国）有限公司首席执行官。于2017年3月1日获委任为和黄医药（中国）有限公司技术委员会委员。
Weiguo SU,has been an executive director of Hutchison China Meditech Limited since 2017 and chief executive officer of Hutchison China Meditech Limited Company since 2022. He is also Hutchmed (China) Limited chief scientific officer since 2012. He is a member of Hutchmed (China) Limited technical committee. Dr. Su has headed all drug discovery and research since he joined Hutchmed (China) Limited company, including master-minding Hutchmed (China) Limited scientific strategy, being a key leader of Hutchmed (China) Limited Oncology/Immunology operations, and responsible for the discovery of each and every small molecule drug candidate in Hutchmed (China) Limited pipeline. Prior to joining Hutchmed (China) Limited in 2005, Dr. Su worked with the U.S. research and development department of Pfizer, Inc. In 2017, Dr. Su was granted the prestigious award by the China Pharmaceutical Innovation and Research Development Association (PhIRDA) as one of the Most Influential Drug R&D Leaders in China. Dr. Su received a bachelor of science degree in chemistry from Fudan University in Shanghai and completed a PhD and post-doctoral fellowship in chemistry at Harvard University under the guidance of Nobel Laureate Professor E. J. Corey.
Edith SHIH
Edith SHIH，自2006年起担任和黄医药(中国)有限公司的非执行董事，自2000年起担任和黄医药(中国)有限公司秘书及集团公司的公司秘书。她亦为和黄医药(中国)有限公司可持续发展委员会主席，并为自2006年起担任和黄医药(中国)有限公司非执行董事、自2000年起担任和黄医药(中国)有限公司秘书及集团公司秘书的成员。她亦为和黄医药(中国)有限公司可持续发展委员会主席及和黄医药（中国）有限公司薪酬委员会成员。她在法律、监管、公司财务、合规和公司治理领域拥有超过40年的经验。她也是长江和记黄埔的执行董事兼公司秘书。她自1989年起任职于长江实业（控股）有限公司（“长和”）集团，自1991年起任职于Hutchison Whampoa有限公司（“HWL”）。长和和HWL此前均在联交所上市，于2015年成为长江和记的全资附属公司。她曾在HWL集团内以各种身份行事，包括HWL的首席集团总法律顾问和公司秘书以及HWL子公司和联营公司的董事和公司秘书。Shih女士还担任和记电讯香港控股有限公司的非执行董事，Hutchison Port Holdings Management Pte. Limited担任和记港口控股信托的受托管理人和PT Duta Intidaya Tbk的专员。此外，Shih女士是和黄医药（中国）有限公司的某些主要股东（即SFO的含义）的董事，以及和黄医药（中国）有限公司的某些主要股东控制的某些公司的董事。上述公司要么是长江和记黄埔的子公司，要么是长江和记黄埔的联营公司，而Shih女士作为长江和记黄埔的董事对其进行监督。她是英国特许管治学会（“CGI”）的前任国际会长和现任理事会成员，也是香港特许管治学会（“HKCGI”）的前任会长和现任名誉顾问。此外，她还担任会计及财务报告委员会流程审查小组主席、香港科技大学理事会副主席以及香港管理协会执行委员会和理事会成员。她也是证券及期货上诉审裁处的成员。Shih女士是一名在英格兰和威尔士、香港和澳大利亚维多利亚州具有律师资格的律师，也是CGI和HKCGI的研究员，担任特许秘书和特许治理薪酬委员会。她在法律、监管、公司财务、合规和公司治理领域拥有超过40年的经验。她也是长江和记黄埔的执行董事兼公司秘书。她自1989年起任职于长江实业（控股）有限公司（“长和”）集团，自1991年起任职于Hutchison Whampoa有限公司（“HWL”）。长和和HWL此前均在联交所上市，于2015年成为长江和记的全资附属公司。她曾在HWL集团内以各种身份行事，包括HWL的首席集团总法律顾问和公司秘书以及HWL子公司和联营公司的董事和公司秘书。Shih女士还担任和记电讯香港控股有限公司的非执行董事，Hutchison Port Holdings Management Pte. Limited担任和记港口控股信托的受托管理人和PT Duta Intidaya Tbk的专员。此外，Shih女士是和黄医药（中国）有限公司的某些主要股东（即SFO所指）的董事，以及和黄医药（中国）有限公司的某些主要股东控制的某些公司的董事。上述公司要么是长江和记黄埔的子公司，要么是长江和记黄埔的联营公司，而Shih女士作为长江和记黄埔的董事对其进行监督。她是英国特许管治学会（“CGI”）的前任国际会长和现任理事会成员，也是香港特许管治学会（“HKCGI”）的前任会长和现任名誉顾问。此外，她还担任会计及财务报告委员会流程审查小组主席、香港科技大学理事会副主席，以及香港管理协会执行委员会和理事会成员。她也是证券及期货上诉审裁处的成员。Shih女士是一名在英格兰和威尔士、香港和澳大利亚维多利亚州具有律师资格的律师，也是CGI和HKCGI的研究员，拥有特许秘书和特许治理专业双重称号。她拥有菲律宾大学理学学士学位和文学硕士学位以及艺术硕士学位和教育硕士学位。
Edith SHIH,has been a non-executive director of Hutchison China Meditech Limited since 2006, the company secretary of Hutchison China Meditech Limited company and the company secretary of group companies since 2000. She is also chairman of Hutchison China Meditech Limited sustainability committee and a member of has been a non-executive director of Hutchison China Meditech Limited since 2006, the company secretary of Hutchison China Meditech Limited company and the company secretary of group companies since 2000. She is also chairman of Hutchison China Meditech Limited sustainability committee and a member of Hutchmed (China) Limited remuneration committee. She has over 40 years of experience in legal, regulatory, corporate finance, compliance and corporate governance fields. She is also executive director and company secretary of CK Hutchison. She has been with the Cheung Kong (Holdings) Limited ("CKH") group since 1989 and with Hutchison Whampoa Limited ("HWL") since 1991. Both CKH and HWL were formerly listed on SEHK and became wholly-owned subsidiaries of CK Hutchison in 2015. She has acted in various capacities within the HWL group, including head group general counsel and company secretary of HWL as well as director and company secretary of HWL subsidiaries and associated companies. Ms. Shih is in addition a non-executive director of Hutchison Telecommunications Hong Kong Holdings Limited, Hutchison Port Holdings Management Pte. Limited as the trustee-manager of Hutchison Port Holdings Trust and a commissioner of PT Duta Intidaya Tbk. In addition, Ms. Shih is a director of certain substantial shareholders (within the meaning of the SFO) of Hutchmed (China) Limited and certain companies controlled by certain substantial shareholders of Hutchmed (China) Limited The aforementioned companies are either subsidiaries or associated companies of CK Hutchison of which Ms. Shih has oversight as a director of CK Hutchison. She is a past international president and current member of the Council of The Chartered Governance Institute ("CGI") as well as a past president and current honorary advisor of The Hong Kong Chartered Governance Institute ("HKCGI"). Further, she is also chairman of the process review panel for the Accounting and Financial Reporting Council, vice-chairman of the Council of The Hong Kong University of Science and Technology, and a member of the Executive Committee and Council of The Hong Kong Management Association. She was also a member of the Securities and Futures Appeal Tribunal. Ms. Shih is a solicitor qualified in England and Wales, Hong Kong and Victoria, Australia and a fellow of both the CGI and HKCGI, holding chartered secretary and chartered governanceremuneration committee. She has over 40 years of experience in legal, regulatory, corporate finance, compliance and corporate governance fields. She is also executive director and company secretary of CK Hutchison. She has been with the Cheung Kong (Holdings) Limited ("CKH") group since 1989 and with Hutchison Whampoa Limited ("HWL") since 1991. Both CKH and HWL were formerly listed on SEHK and became wholly-owned subsidiaries of CK Hutchison in 2015. She has acted in various capacities within the HWL group, including head group general counsel and company secretary of HWL as well as director and company secretary of HWL subsidiaries and associated companies. Ms. Shih is in addition a non-executive director of Hutchison Telecommunications Hong Kong Holdings Limited, Hutchison Port Holdings Management Pte. Limited as the trustee-manager of Hutchison Port Holdings Trust and a commissioner of PT Duta Intidaya Tbk. In addition, Ms. Shih is a director of certain substantial shareholders (within the meaning of the SFO) of Hutchmed (China) Limited and certain companies controlled by certain substantial shareholders of Hutchmed (China) Limited The aforementioned companies are either subsidiaries or associated companies of CK Hutchison of which Ms. Shih has oversight as a director of CK Hutchison. She is a past international president and current member of the Council of The Chartered Governance Institute ("CGI") as well as a past president and current honorary advisor of The Hong Kong Chartered Governance Institute ("HKCGI"). Further, she is also chairman of the process review panel for the Accounting and Financial Reporting Council, vice-chairman of the Council of The Hong Kong University of Science and Technology, and a member of the Executive Committee and Council of The Hong Kong Management Association. She was also a member of the Securities and Futures Appeal Tribunal. Ms. Shih is a solicitor qualified in England and Wales, Hong Kong and Victoria, Australia and a fellow of both the CGI and HKCGI, holding chartered secretary and chartered governance professional dual designations. She holds a bachelor of science degree and a master of arts degree from the University of the Philippines as well as a master of arts degree and a master of education degree from Columbia University, New York.
Edith SHIH，自2006年起担任和黄医药(中国)有限公司的非执行董事，自2000年起担任和黄医药(中国)有限公司秘书及集团公司的公司秘书。她亦为和黄医药(中国)有限公司可持续发展委员会主席，并为自2006年起担任和黄医药(中国)有限公司非执行董事、自2000年起担任和黄医药(中国)有限公司秘书及集团公司秘书的成员。她亦为和黄医药(中国)有限公司可持续发展委员会主席及和黄医药（中国）有限公司薪酬委员会成员。她在法律、监管、公司财务、合规和公司治理领域拥有超过40年的经验。她也是长江和记黄埔的执行董事兼公司秘书。她自1989年起任职于长江实业（控股）有限公司（“长和”）集团，自1991年起任职于Hutchison Whampoa有限公司（“HWL”）。长和和HWL此前均在联交所上市，于2015年成为长江和记的全资附属公司。她曾在HWL集团内以各种身份行事，包括HWL的首席集团总法律顾问和公司秘书以及HWL子公司和联营公司的董事和公司秘书。Shih女士还担任和记电讯香港控股有限公司的非执行董事，Hutchison Port Holdings Management Pte. Limited担任和记港口控股信托的受托管理人和PT Duta Intidaya Tbk的专员。此外，Shih女士是和黄医药（中国）有限公司的某些主要股东（即SFO的含义）的董事，以及和黄医药（中国）有限公司的某些主要股东控制的某些公司的董事。上述公司要么是长江和记黄埔的子公司，要么是长江和记黄埔的联营公司，而Shih女士作为长江和记黄埔的董事对其进行监督。她是英国特许管治学会（“CGI”）的前任国际会长和现任理事会成员，也是香港特许管治学会（“HKCGI”）的前任会长和现任名誉顾问。此外，她还担任会计及财务报告委员会流程审查小组主席、香港科技大学理事会副主席以及香港管理协会执行委员会和理事会成员。她也是证券及期货上诉审裁处的成员。Shih女士是一名在英格兰和威尔士、香港和澳大利亚维多利亚州具有律师资格的律师，也是CGI和HKCGI的研究员，担任特许秘书和特许治理薪酬委员会。她在法律、监管、公司财务、合规和公司治理领域拥有超过40年的经验。她也是长江和记黄埔的执行董事兼公司秘书。她自1989年起任职于长江实业（控股）有限公司（“长和”）集团，自1991年起任职于Hutchison Whampoa有限公司（“HWL”）。长和和HWL此前均在联交所上市，于2015年成为长江和记的全资附属公司。她曾在HWL集团内以各种身份行事，包括HWL的首席集团总法律顾问和公司秘书以及HWL子公司和联营公司的董事和公司秘书。Shih女士还担任和记电讯香港控股有限公司的非执行董事，Hutchison Port Holdings Management Pte. Limited担任和记港口控股信托的受托管理人和PT Duta Intidaya Tbk的专员。此外，Shih女士是和黄医药（中国）有限公司的某些主要股东（即SFO所指）的董事，以及和黄医药（中国）有限公司的某些主要股东控制的某些公司的董事。上述公司要么是长江和记黄埔的子公司，要么是长江和记黄埔的联营公司，而Shih女士作为长江和记黄埔的董事对其进行监督。她是英国特许管治学会（“CGI”）的前任国际会长和现任理事会成员，也是香港特许管治学会（“HKCGI”）的前任会长和现任名誉顾问。此外，她还担任会计及财务报告委员会流程审查小组主席、香港科技大学理事会副主席，以及香港管理协会执行委员会和理事会成员。她也是证券及期货上诉审裁处的成员。Shih女士是一名在英格兰和威尔士、香港和澳大利亚维多利亚州具有律师资格的律师，也是CGI和HKCGI的研究员，拥有特许秘书和特许治理专业双重称号。她拥有菲律宾大学理学学士学位和文学硕士学位以及艺术硕士学位和教育硕士学位。
Edith SHIH,has been a non-executive director of Hutchison China Meditech Limited since 2006, the company secretary of Hutchison China Meditech Limited company and the company secretary of group companies since 2000. She is also chairman of Hutchison China Meditech Limited sustainability committee and a member of has been a non-executive director of Hutchison China Meditech Limited since 2006, the company secretary of Hutchison China Meditech Limited company and the company secretary of group companies since 2000. She is also chairman of Hutchison China Meditech Limited sustainability committee and a member of Hutchmed (China) Limited remuneration committee. She has over 40 years of experience in legal, regulatory, corporate finance, compliance and corporate governance fields. She is also executive director and company secretary of CK Hutchison. She has been with the Cheung Kong (Holdings) Limited ("CKH") group since 1989 and with Hutchison Whampoa Limited ("HWL") since 1991. Both CKH and HWL were formerly listed on SEHK and became wholly-owned subsidiaries of CK Hutchison in 2015. She has acted in various capacities within the HWL group, including head group general counsel and company secretary of HWL as well as director and company secretary of HWL subsidiaries and associated companies. Ms. Shih is in addition a non-executive director of Hutchison Telecommunications Hong Kong Holdings Limited, Hutchison Port Holdings Management Pte. Limited as the trustee-manager of Hutchison Port Holdings Trust and a commissioner of PT Duta Intidaya Tbk. In addition, Ms. Shih is a director of certain substantial shareholders (within the meaning of the SFO) of Hutchmed (China) Limited and certain companies controlled by certain substantial shareholders of Hutchmed (China) Limited The aforementioned companies are either subsidiaries or associated companies of CK Hutchison of which Ms. Shih has oversight as a director of CK Hutchison. She is a past international president and current member of the Council of The Chartered Governance Institute ("CGI") as well as a past president and current honorary advisor of The Hong Kong Chartered Governance Institute ("HKCGI"). Further, she is also chairman of the process review panel for the Accounting and Financial Reporting Council, vice-chairman of the Council of The Hong Kong University of Science and Technology, and a member of the Executive Committee and Council of The Hong Kong Management Association. She was also a member of the Securities and Futures Appeal Tribunal. Ms. Shih is a solicitor qualified in England and Wales, Hong Kong and Victoria, Australia and a fellow of both the CGI and HKCGI, holding chartered secretary and chartered governanceremuneration committee. She has over 40 years of experience in legal, regulatory, corporate finance, compliance and corporate governance fields. She is also executive director and company secretary of CK Hutchison. She has been with the Cheung Kong (Holdings) Limited ("CKH") group since 1989 and with Hutchison Whampoa Limited ("HWL") since 1991. Both CKH and HWL were formerly listed on SEHK and became wholly-owned subsidiaries of CK Hutchison in 2015. She has acted in various capacities within the HWL group, including head group general counsel and company secretary of HWL as well as director and company secretary of HWL subsidiaries and associated companies. Ms. Shih is in addition a non-executive director of Hutchison Telecommunications Hong Kong Holdings Limited, Hutchison Port Holdings Management Pte. Limited as the trustee-manager of Hutchison Port Holdings Trust and a commissioner of PT Duta Intidaya Tbk. In addition, Ms. Shih is a director of certain substantial shareholders (within the meaning of the SFO) of Hutchmed (China) Limited and certain companies controlled by certain substantial shareholders of Hutchmed (China) Limited The aforementioned companies are either subsidiaries or associated companies of CK Hutchison of which Ms. Shih has oversight as a director of CK Hutchison. She is a past international president and current member of the Council of The Chartered Governance Institute ("CGI") as well as a past president and current honorary advisor of The Hong Kong Chartered Governance Institute ("HKCGI"). Further, she is also chairman of the process review panel for the Accounting and Financial Reporting Council, vice-chairman of the Council of The Hong Kong University of Science and Technology, and a member of the Executive Committee and Council of The Hong Kong Management Association. She was also a member of the Securities and Futures Appeal Tribunal. Ms. Shih is a solicitor qualified in England and Wales, Hong Kong and Victoria, Australia and a fellow of both the CGI and HKCGI, holding chartered secretary and chartered governance professional dual designations. She holds a bachelor of science degree and a master of arts degree from the University of the Philippines as well as a master of arts degree and a master of education degree from Columbia University, New York.
Paul Rutherford CARTER
Paul Rutherford CARTER，自2017年起担任和黄医药(中国)有限公司高级独立非执行董事。兼任和黄医药(中国)有限公司薪酬委员会主席及和黄医药(中国)有限公司审核委员会及技术委员会成员。他在医药行业拥有超过26年的经验。2006年至2016年，Carter先生在以研究为基础的生物制药公司吉利德科学公司（“吉利德”）担任过多个高级管理职务，最后一个职位是商业运营执行副总裁。在担任这一职务期间，Carter先生领导了负责吉利德所有产品的发布和商业化的全球商业组织。他还曾在葛兰素史克（GlaxoSmithKline Plc，现为GSK Plc.）担任高级主管。现任Immatics N.V。、Kyowa Kirin International PLC董事。他是Evox Therapeutics的董事长，也是几家活跃在生命科学领域的公司的留任顾问。曾任Alder Biopharmaceuticals，Inc、万灵科 PLC和VectivBio Holding AG的董事。
Paul Rutherford CARTER,has been a senior independent non-executive director of Hutchmed (China) Limited since 2017. He is also chairman of Hutchmed (China) Limited remuneration committee and a member of Hutchmed (China) Limited audit committee and technical committee. He has more than 26 years of experience in the pharmaceutical industry. From 2006 to 2016, Mr. Carter served in various senior executive roles at Gilead Sciences, Inc. ("Gilead"), a research-based biopharmaceutical company, with the last position as executive vice president, commercial operations. In this role, Mr. Carter headed the worldwide commercial organization responsible for the launch and commercialization of all of the products of Gilead. He also worked as a senior executive at GlaxoSmithKline Plc (currently GSK Plc.). He is currently a director of Immatics N.V. and Kyowa Kirin International Plc. He is the chairman of Evox Therapeutics and a retained advisor to several firms active in the life sciences sector. He was formerly a director of Alder Biopharmaceuticals, Inc, Mallinckrodt plc and VectivBio Holding AG.
Paul Rutherford CARTER，自2017年起担任和黄医药(中国)有限公司高级独立非执行董事。兼任和黄医药(中国)有限公司薪酬委员会主席及和黄医药(中国)有限公司审核委员会及技术委员会成员。他在医药行业拥有超过26年的经验。2006年至2016年，Carter先生在以研究为基础的生物制药公司吉利德科学公司（“吉利德”）担任过多个高级管理职务，最后一个职位是商业运营执行副总裁。在担任这一职务期间，Carter先生领导了负责吉利德所有产品的发布和商业化的全球商业组织。他还曾在葛兰素史克（GlaxoSmithKline Plc，现为GSK Plc.）担任高级主管。现任Immatics N.V。、Kyowa Kirin International PLC董事。他是Evox Therapeutics的董事长，也是几家活跃在生命科学领域的公司的留任顾问。曾任Alder Biopharmaceuticals，Inc、万灵科 PLC和VectivBio Holding AG的董事。
Paul Rutherford CARTER,has been a senior independent non-executive director of Hutchmed (China) Limited since 2017. He is also chairman of Hutchmed (China) Limited remuneration committee and a member of Hutchmed (China) Limited audit committee and technical committee. He has more than 26 years of experience in the pharmaceutical industry. From 2006 to 2016, Mr. Carter served in various senior executive roles at Gilead Sciences, Inc. ("Gilead"), a research-based biopharmaceutical company, with the last position as executive vice president, commercial operations. In this role, Mr. Carter headed the worldwide commercial organization responsible for the launch and commercialization of all of the products of Gilead. He also worked as a senior executive at GlaxoSmithKline Plc (currently GSK Plc.). He is currently a director of Immatics N.V. and Kyowa Kirin International Plc. He is the chairman of Evox Therapeutics and a retained advisor to several firms active in the life sciences sector. He was formerly a director of Alder Biopharmaceuticals, Inc, Mallinckrodt plc and VectivBio Holding AG.
Dan ELDAR
Dan Eldar自2016年起担任非执行董事。他是Hutchison水务以色列有限公司的执行董事，该公司是CK Hutchison集团的子公司，专注于大型项目，包括海水淡化，废水处理和中水回用。之前他还是Leumi Card的独立非执行董事，Leumi Card是以色列领先的信用卡公司之一Leumi Le-Israel B.M的子公司。Eldar博士拥有哈佛大学政府哲学博士学位，哈佛大学政府文学硕士学位，耶路撒冷希伯来大学政治学和公共管理文学硕士学位以及政治学文学学士学位。自2016年8月起担任和黄医药（中国）有限公司非执行董事。于2024年5月17日委任为和黄医药(中国)有限公司董事会主席。
Dan ELDAR,has been a non-executive director of Hutchison China Meditech Limited company since 2016. He is also the Chairman of Hutchison China Meditech Limited Company, a member of Hutchmed (China) Limited nomination committee and technical committee. He has more than 30 years of experience as a senior executive, leading global operations in biotechnology, healthcare, telecommunications, and water. He is an executive director of Hutchison Water Israel E.P.C Ltd, an associate of CK Hutchison Group, which focuses on large scale desalination and hydro-electric projects. Dr. Eldar is a director of certain companies controlled by certain substantial shareholders (within the meaning of the Securities and Futures Ordinance ("SFO")). Dr. Eldar received a doctor of philosophy degree in government from Harvard University, master of arts degree in government from Harvard University, master of arts degree in political science and public administration from the Hebrew University of Jerusalem and a bachelor of arts degree in political science from the Hebrew University of Jerusalem.
Dan Eldar自2016年起担任非执行董事。他是Hutchison水务以色列有限公司的执行董事，该公司是CK Hutchison集团的子公司，专注于大型项目，包括海水淡化，废水处理和中水回用。之前他还是Leumi Card的独立非执行董事，Leumi Card是以色列领先的信用卡公司之一Leumi Le-Israel B.M的子公司。Eldar博士拥有哈佛大学政府哲学博士学位，哈佛大学政府文学硕士学位，耶路撒冷希伯来大学政治学和公共管理文学硕士学位以及政治学文学学士学位。自2016年8月起担任和黄医药（中国）有限公司非执行董事。于2024年5月17日委任为和黄医药(中国)有限公司董事会主席。
Dan ELDAR,has been a non-executive director of Hutchison China Meditech Limited company since 2016. He is also the Chairman of Hutchison China Meditech Limited Company, a member of Hutchmed (China) Limited nomination committee and technical committee. He has more than 30 years of experience as a senior executive, leading global operations in biotechnology, healthcare, telecommunications, and water. He is an executive director of Hutchison Water Israel E.P.C Ltd, an associate of CK Hutchison Group, which focuses on large scale desalination and hydro-electric projects. Dr. Eldar is a director of certain companies controlled by certain substantial shareholders (within the meaning of the Securities and Futures Ordinance ("SFO")). Dr. Eldar received a doctor of philosophy degree in government from Harvard University, master of arts degree in government from Harvard University, master of arts degree in political science and public administration from the Hebrew University of Jerusalem and a bachelor of arts degree in political science from the Hebrew University of Jerusalem.
Ling YANG
Ling Yang，ADICON控股有限公司主席兼非执行董事（香港交易所代码：9860）；Shenzhen Salubris Pharmaceuticals Co., Ltd.（深交所股票代码：002294）董事；Ambio Pharmaceuticals和Ambio, Inc.的非执行董事；Adicon （Hangzhou） Clinical Laboratories Co., Ltd.、Aidiken （Hangzhou） Biotech Co., Ltd董事长；Adicon国际有限公司和Manson Grand国际有限公司董事。她曾担任Ambio Holdings, Inc.的非执行董事。Yang女士曾任职于KKR亚洲有限公司，其最后职位为主要负责KKR亚洲有限公司的投资。她还曾担任Carlyle U.S. leveraged buyout healthcare group of Carlyle的合伙人；担任Goldman Sachs Group, Inc.部门的分析师。她于summa cum laude毕业，是Phi Beta Kappa的成员，拥有史密斯学院（Smith College）的经济学和计算机科学学士学位，并获得哈佛商学院（Harvard business School）的工商管理硕士学位。
Ling YANG,has been a non-executive director of Hutchison China Meditech Limited company since 2023. She has been the managing director of Carlyle since 2017 and its head of China since 2024, in charge of advising in healthcare investment and portfolio activities of Carlyle in China. She is also chairwoman and non-executive director of ADICON Holdings Limited. Prior to Carlyle Group, Ms. Yang worked in private equity at KKR Asia Limited and in investment banking at Goldman Sachs in the U.S. She was formerly a director of Shenzhen Salubris Pharmaceuticals Co., Ltd. Ms. Yang graduated summa cum laude and is a member of Phi Beta Kappa with a bachelor's degree in economics and computer science from Smith College and she received her master of business administration degree from Harvard Business School.
Ling Yang，ADICON控股有限公司主席兼非执行董事（香港交易所代码：9860）；Shenzhen Salubris Pharmaceuticals Co., Ltd.（深交所股票代码：002294）董事；Ambio Pharmaceuticals和Ambio, Inc.的非执行董事；Adicon （Hangzhou） Clinical Laboratories Co., Ltd.、Aidiken （Hangzhou） Biotech Co., Ltd董事长；Adicon国际有限公司和Manson Grand国际有限公司董事。她曾担任Ambio Holdings, Inc.的非执行董事。Yang女士曾任职于KKR亚洲有限公司，其最后职位为主要负责KKR亚洲有限公司的投资。她还曾担任Carlyle U.S. leveraged buyout healthcare group of Carlyle的合伙人；担任Goldman Sachs Group, Inc.部门的分析师。她于summa cum laude毕业，是Phi Beta Kappa的成员，拥有史密斯学院（Smith College）的经济学和计算机科学学士学位，并获得哈佛商学院（Harvard business School）的工商管理硕士学位。
Ling YANG,has been a non-executive director of Hutchison China Meditech Limited company since 2023. She has been the managing director of Carlyle since 2017 and its head of China since 2024, in charge of advising in healthcare investment and portfolio activities of Carlyle in China. She is also chairwoman and non-executive director of ADICON Holdings Limited. Prior to Carlyle Group, Ms. Yang worked in private equity at KKR Asia Limited and in investment banking at Goldman Sachs in the U.S. She was formerly a director of Shenzhen Salubris Pharmaceuticals Co., Ltd. Ms. Yang graduated summa cum laude and is a member of Phi Beta Kappa with a bachelor's degree in economics and computer science from Smith College and she received her master of business administration degree from Harvard Business School.
言思雅
言思雅，博士现年目前为宏声医疗科技（香港）有限公司的主席兼联合创办人，该公司事注于开发用于眼部无创用药之超声波技术。她亦为Asia Fintech Angels的联合创办人，该公司专门从事投资于初期的金融科技公司。此外，言思雅博士亦为Overstone Associates Limited的独立非执行董事，该公司是一家英国领先的数据科学供应商，为专注于艺术行业的金融机构提供服务。言思雅博士为香港联合交易所有限公司上市委员会主席。她亦于公共服务方面担任职务，包括香港工商专业联会医疗保健委员会成员及数码港创业中心咨询小组成员，以及于创科应用基金香港企业支援计划担任评审委员会委员。言思雅博士于高盛及汇丰资产管理展开其于金融方面的职业生涯。言思雅博士为伦敦大学内外全科医学士（MBBS）并持有耶鲁大学工商管理硕士学位及香港大学治疗学与医学研究生文凭。于2024年05月13日获委任为和黄医药（中国）有限公司独立非执行董事。于2025年2月4日获委任为和黄医药（中国）有限公司审核委员会委员。于2024年05月13日获委任为和黄医药(中国)有限公司技术委员会委员。
Renu BHATIA,has been an independent non-executive director of Hutchison China Meditech Limited company since May 2024. She is also a member of the audit committee and technical committee of Hutchison China Meditech Limited company. She is the chairman and co-founder of Opharmic Technology (HK) Ltd, a company focusing on the development of ultrasound technology for non-invasive drug delivery to the eyes. She is also co-founder of Asia Fintech Angels which invested in early stage fintech companies. In addition, Dr. Bhatia is an independent non-executive director of Overstone Associates Limited, a UK based data science provider to financial institutions focused on the art industry. Dr. Bhatia is the chairman of the Listing Committee of The Stock Exchange of Hong Kong Limited. She also holds positions in public service including membership of the Business Professional Federation Healthcare Committee and acting as an assessor for the Hong Kong Enterprise Support Scheme Assessment Panel of the Innovation and Technology Fund. She was a member of the Board of Review (Inland Revenue Ordinance) and the Cyberport Entrepreneurship Centre Advisory Group. Dr. Bhatia started her career in finance at Goldman Sachs and HSBC Asset Management. Dr. Bhatia is a doctor of medicine from the University of London and holds a master of business administration degree from Yale University, and a postgraduate diploma in therapeutics and medicine from The University of Hong Kong.
言思雅，博士现年目前为宏声医疗科技（香港）有限公司的主席兼联合创办人，该公司事注于开发用于眼部无创用药之超声波技术。她亦为Asia Fintech Angels的联合创办人，该公司专门从事投资于初期的金融科技公司。此外，言思雅博士亦为Overstone Associates Limited的独立非执行董事，该公司是一家英国领先的数据科学供应商，为专注于艺术行业的金融机构提供服务。言思雅博士为香港联合交易所有限公司上市委员会主席。她亦于公共服务方面担任职务，包括香港工商专业联会医疗保健委员会成员及数码港创业中心咨询小组成员，以及于创科应用基金香港企业支援计划担任评审委员会委员。言思雅博士于高盛及汇丰资产管理展开其于金融方面的职业生涯。言思雅博士为伦敦大学内外全科医学士（MBBS）并持有耶鲁大学工商管理硕士学位及香港大学治疗学与医学研究生文凭。于2024年05月13日获委任为和黄医药（中国）有限公司独立非执行董事。于2025年2月4日获委任为和黄医药（中国）有限公司审核委员会委员。于2024年05月13日获委任为和黄医药(中国)有限公司技术委员会委员。
Renu BHATIA,has been an independent non-executive director of Hutchison China Meditech Limited company since May 2024. She is also a member of the audit committee and technical committee of Hutchison China Meditech Limited company. She is the chairman and co-founder of Opharmic Technology (HK) Ltd, a company focusing on the development of ultrasound technology for non-invasive drug delivery to the eyes. She is also co-founder of Asia Fintech Angels which invested in early stage fintech companies. In addition, Dr. Bhatia is an independent non-executive director of Overstone Associates Limited, a UK based data science provider to financial institutions focused on the art industry. Dr. Bhatia is the chairman of the Listing Committee of The Stock Exchange of Hong Kong Limited. She also holds positions in public service including membership of the Business Professional Federation Healthcare Committee and acting as an assessor for the Hong Kong Enterprise Support Scheme Assessment Panel of the Innovation and Technology Fund. She was a member of the Board of Review (Inland Revenue Ordinance) and the Cyberport Entrepreneurship Centre Advisory Group. Dr. Bhatia started her career in finance at Goldman Sachs and HSBC Asset Management. Dr. Bhatia is a doctor of medicine from the University of London and holds a master of business administration degree from Yale University, and a postgraduate diploma in therapeutics and medicine from The University of Hong Kong.
CHENG Chig Fung, Johnny
CHENG Chig Fung, Johnny，自2011年起担任和黄医药(中国)有限公司执行董事，自2008年起担任和黄医药(中国)有限公司首席财务官。他是和黄医药(中国)有限公司可持续发展委员会成员。在加入和黄医药(中国)有限公司之前，CHENG先生曾任百时美施贵宝中国财务副总裁，并于2006年末至2008年期间担任Sino-American Shanghai Squibb Pharmaceuticals Ltd.和上海Bristol-Myers Squibb （China） Investment Co. Ltd. 的董事。CHENG先生的职业生涯始于澳大利亚普华永道会计师事务所（现为普华永道会计师事务所）的审计师，随后在北京毕马威会计师事务所任职，之后在雀巢中国工作了八年，在那里他负责多个财务和控制职能部门的各种业务。CHENG先生获得阿德莱德大学会计学专业经济学学士学位，并且是澳大利亚和新西兰特许会计师事务所（“CAANZ”）的合伙人。
CHENG Chig Fung, Johnny,has been an executive director of Hutchison China Meditech Limited since 2011 and Hutchmed (China) Limited chief financial officer since 2008. He is a member of Hutchison China Meditech Limited sustainability committee. Prior to joining Hutchmed (China) Limited company, Mr. Cheng was vice president, finance of Bristol Myers Squibb in China and was a director of Sino-American Shanghai Squibb Pharmaceuticals Ltd. and Bristol-Myers Squibb (China) Investment Co. Ltd. in Shanghai between late 2006 and 2008. Mr. Cheng started his career as an auditor with Price Waterhouse (currently PricewaterhouseCoopers) in Australia and then KPMG in Beijing before spending eight years with Nestlé China where he was in charge of a number of finance and control functions in various operations. Mr. Cheng received a bachelor of economics, accounting major from the University of Adelaide and is an associate of Chartered Accountants Australia and New Zealand ("CAANZ").
CHENG Chig Fung, Johnny，自2011年起担任和黄医药(中国)有限公司执行董事，自2008年起担任和黄医药(中国)有限公司首席财务官。他是和黄医药(中国)有限公司可持续发展委员会成员。在加入和黄医药(中国)有限公司之前，CHENG先生曾任百时美施贵宝中国财务副总裁，并于2006年末至2008年期间担任Sino-American Shanghai Squibb Pharmaceuticals Ltd.和上海Bristol-Myers Squibb （China） Investment Co. Ltd. 的董事。CHENG先生的职业生涯始于澳大利亚普华永道会计师事务所（现为普华永道会计师事务所）的审计师，随后在北京毕马威会计师事务所任职，之后在雀巢中国工作了八年，在那里他负责多个财务和控制职能部门的各种业务。CHENG先生获得阿德莱德大学会计学专业经济学学士学位，并且是澳大利亚和新西兰特许会计师事务所（“CAANZ”）的合伙人。
CHENG Chig Fung, Johnny,has been an executive director of Hutchison China Meditech Limited since 2011 and Hutchmed (China) Limited chief financial officer since 2008. He is a member of Hutchison China Meditech Limited sustainability committee. Prior to joining Hutchmed (China) Limited company, Mr. Cheng was vice president, finance of Bristol Myers Squibb in China and was a director of Sino-American Shanghai Squibb Pharmaceuticals Ltd. and Bristol-Myers Squibb (China) Investment Co. Ltd. in Shanghai between late 2006 and 2008. Mr. Cheng started his career as an auditor with Price Waterhouse (currently PricewaterhouseCoopers) in Australia and then KPMG in Beijing before spending eight years with Nestlé China where he was in charge of a number of finance and control functions in various operations. Mr. Cheng received a bachelor of economics, accounting major from the University of Adelaide and is an associate of Chartered Accountants Australia and New Zealand ("CAANZ").
MOK Shu Kam, Tony
MOK Shu Kam, Tony，自2017年起担任和黄医药（中国）有限公司的独立非执行董事。Mok教授拥有超过35年的临床肿瘤学经验，主要研究兴趣集中在肺癌的生物标志物和分子靶向治疗。现任香港中文大学李书帆医学基金会获委任教授及临床肿瘤学系主任。莫教授在国际同行评议期刊上发表了300多篇文章，并发表了多篇社论和教科书。2018年，Mok教授是首位获得欧洲医学肿瘤学会（“ESMO”）终身成就奖的中国人，这是授予癌症研究人员的最负盛名的国际荣誉和认可之一，以表彰他在全球肺癌研究方面的贡献和领导作用。2023年，莫教授因在肺癌研究方面的贡献，荣获第六届霍英东奖——世界杰出中国医生奖。Mok教授是阿斯利康 PLC的非执行董事、Lunit USA Inc.的非执行独立董事以及Prenetics Global Limited（“Prenetics”）科学顾问委员会的成员。他是Sanomics Limited（于2021年被ACT Genomics Holdings Ltd.收购）和Aurora Tele-Oncology Limited的联合创始人。他也是Insighta Holdings Limited的董事。曾任ASCO董事会董事、中国临床肿瘤学会指导委员会委员、国际肺癌研究协会前任会长、ACT Genomics Holdings Ltd.董事会主席，直至2022年被Prenetics收购。莫教授也与中国肿瘤界有密切联系，曾获广东省人民医院荣誉教授、北京协和医院客座教授和上海交通大学客座教授、福建省肿瘤医院特聘教授。他在加拿大阿尔伯塔大学获得医学科学学士学位和医学博士学位。他也是加拿大皇家内科医生和外科医生学院、香港内科医生学院、香港医学科学院、爱丁堡皇家内科医生学院和ASCO的院士。
MOK Shu Kam, Tony,has been an independent non-executive director of Hutchison China Meditech Limited since 2017. Professor Mok has more than 35 years of experience in clinical oncology with his main research interest focusing on biomarker and molecular targeted therapy in lung cancer. He is currently Li Shu Fan Medical Foundation named professor and chairman of department of clinical oncology at The Chinese University of Hong Kong. Professor Mok has contributed to over 300 articles in international peer-reviewed journals, as well as multiple editorials and textbooks. In 2018, Professor Mok was the first Chinese to be bestowed with the European Society for Medical Oncology ("ESMO") Lifetime Achievement Award, one of the most prestigious international honors and recognitions given to cancer researchers, for his contribution to and leadership in lung cancer research worldwide. In 2023, Professor Mok was awarded The Sixth Fok Ying-Tung Prize – The World Outstanding Chinese Doctor Award, for his contribution in lung cancer research. Professor Mok is a non-executive director of AstraZeneca PLC, a non-executive independent director of Lunit USA Inc. and a member of the scientific advisory board of Prenetics Global Limited ("Prenetics"). He is co-founder of Sanomics Limited (acquired by ACT Genomics Holdings Ltd. in 2021) and Aurora Tele-Oncology Limited. He is also a director of Insighta Holdings Limited. He was formerly a board director of ASCO, a steering committee member of the Chinese Society of Clinical Oncology, past president of the International Association for the Study of Lung Cancer, and the chairman of the board of ACT Genomics Holdings Ltd. until it was acquired by Prenetics in 2022. Professor Mok is also closely affiliated with the oncology community in China and has been awarded an Honorary Professorship at Guangdong Province People's Hospital, Guest Professorship at Peking Union Medical College Hospital and Visiting Professorship at Shanghai Jiao Tong University and Distinguished Professorship at Fujian Cancer Hospital. He received his bachelor of medical science degree and a doctor of medicine from University of Alberta, Canada. He is also a fellow of the Royal College of Physicians and Surgeons of Canada, Hong Kong College of Physicians, Hong Kong Academy of Medicine, Royal College of Physicians of Edinburgh and ASCO.
MOK Shu Kam, Tony，自2017年起担任和黄医药（中国）有限公司的独立非执行董事。Mok教授拥有超过35年的临床肿瘤学经验，主要研究兴趣集中在肺癌的生物标志物和分子靶向治疗。现任香港中文大学李书帆医学基金会获委任教授及临床肿瘤学系主任。莫教授在国际同行评议期刊上发表了300多篇文章，并发表了多篇社论和教科书。2018年，Mok教授是首位获得欧洲医学肿瘤学会（“ESMO”）终身成就奖的中国人，这是授予癌症研究人员的最负盛名的国际荣誉和认可之一，以表彰他在全球肺癌研究方面的贡献和领导作用。2023年，莫教授因在肺癌研究方面的贡献，荣获第六届霍英东奖——世界杰出中国医生奖。Mok教授是阿斯利康 PLC的非执行董事、Lunit USA Inc.的非执行独立董事以及Prenetics Global Limited（“Prenetics”）科学顾问委员会的成员。他是Sanomics Limited（于2021年被ACT Genomics Holdings Ltd.收购）和Aurora Tele-Oncology Limited的联合创始人。他也是Insighta Holdings Limited的董事。曾任ASCO董事会董事、中国临床肿瘤学会指导委员会委员、国际肺癌研究协会前任会长、ACT Genomics Holdings Ltd.董事会主席，直至2022年被Prenetics收购。莫教授也与中国肿瘤界有密切联系，曾获广东省人民医院荣誉教授、北京协和医院客座教授和上海交通大学客座教授、福建省肿瘤医院特聘教授。他在加拿大阿尔伯塔大学获得医学科学学士学位和医学博士学位。他也是加拿大皇家内科医生和外科医生学院、香港内科医生学院、香港医学科学院、爱丁堡皇家内科医生学院和ASCO的院士。
MOK Shu Kam, Tony,has been an independent non-executive director of Hutchison China Meditech Limited since 2017. Professor Mok has more than 35 years of experience in clinical oncology with his main research interest focusing on biomarker and molecular targeted therapy in lung cancer. He is currently Li Shu Fan Medical Foundation named professor and chairman of department of clinical oncology at The Chinese University of Hong Kong. Professor Mok has contributed to over 300 articles in international peer-reviewed journals, as well as multiple editorials and textbooks. In 2018, Professor Mok was the first Chinese to be bestowed with the European Society for Medical Oncology ("ESMO") Lifetime Achievement Award, one of the most prestigious international honors and recognitions given to cancer researchers, for his contribution to and leadership in lung cancer research worldwide. In 2023, Professor Mok was awarded The Sixth Fok Ying-Tung Prize – The World Outstanding Chinese Doctor Award, for his contribution in lung cancer research. Professor Mok is a non-executive director of AstraZeneca PLC, a non-executive independent director of Lunit USA Inc. and a member of the scientific advisory board of Prenetics Global Limited ("Prenetics"). He is co-founder of Sanomics Limited (acquired by ACT Genomics Holdings Ltd. in 2021) and Aurora Tele-Oncology Limited. He is also a director of Insighta Holdings Limited. He was formerly a board director of ASCO, a steering committee member of the Chinese Society of Clinical Oncology, past president of the International Association for the Study of Lung Cancer, and the chairman of the board of ACT Genomics Holdings Ltd. until it was acquired by Prenetics in 2022. Professor Mok is also closely affiliated with the oncology community in China and has been awarded an Honorary Professorship at Guangdong Province People's Hospital, Guest Professorship at Peking Union Medical College Hospital and Visiting Professorship at Shanghai Jiao Tong University and Distinguished Professorship at Fujian Cancer Hospital. He received his bachelor of medical science degree and a doctor of medicine from University of Alberta, Canada. He is also a fellow of the Royal College of Physicians and Surgeons of Canada, Hong Kong College of Physicians, Hong Kong Academy of Medicine, Royal College of Physicians of Edinburgh and ASCO.
席纪伦
席纪伦(Graeme Jack)，自2017年3月起担任Hutchmed (China) Limited独立非执行董事。他亦为审核委员会主席、提名委员会及薪酬委员会成员。他于财务及审计方面拥有逾40年经验。于罗兵咸永道会计师事务所渡过逾33年的杰出职业生涯后，他于2006年以合伙人身份退休。他现任The Greenbrier Companies,Inc.（一家为货运铁路运输市场提供设备及服务的国际供应商，于纽约证券交易所上市，股份代号：GBX）、和记港口信托（一家深水货柜码头开发商及营运商，于新加坡证券交易所上市，股份代号：NS8U）的托管人-经理Hutchison Port Holdings Management Pte.Limited及中远海运发展股份有限公司（前称‘中海集装箱运输股份有限公司’，一个主营船只及货柜租赁的综合金融服务平台，于上海证券交易所（股份代号：601866）及香港联交所（股份代号：2866）上市）的独立非执行董事。他于1973年5月在澳洲新南威尔士大学取得商学学士学位，并自1987年3月起为香港会计师公会的资深会员及自1976年9月起为澳洲及新西兰特许会计师公会的会员。于2024年12月13日获委任为长江和记实业有限公司独立非执行董事及审核委员会委员。
Graeme Jack,has been an independent non-executive director of Hutchmed (China) Limited since 2017. He is also chairman of Hutchmed (China) Limited audit committee and a member of Hutchmed (China) Limited nomination committee and remuneration committee. He has more than 40 years of experience in finance and audit. He retired as partner of PricewaterhouseCoopers in 2006 after a distinguished career with the firm for over 33 years. He is currently an independent non-executive director of The Greenbrier Companies, Inc. (an international supplier of equipment and services to the freight rail transportation markets). He was formerly a director of COSCO SHIPPING Development Co., Ltd. (formerly known as "China Shipping Container Lines Company Limited", an integrated financial services platform principally engaged in vessel and container leasing) and Hutchison Port Holdings Management Pte. Limited as the trustee-manager of Hutchison Port Holdings Trust (a developer and operator of deep water container terminals). Mr. Jack received a bachelor of commerce degree from University of New South Wales, Australia and is a fellow of the Hong Kong Institute of Certified Public Accountants and an associate of Chartered Accountants Australia and New Zealand.
席纪伦(Graeme Jack)，自2017年3月起担任Hutchmed (China) Limited独立非执行董事。他亦为审核委员会主席、提名委员会及薪酬委员会成员。他于财务及审计方面拥有逾40年经验。于罗兵咸永道会计师事务所渡过逾33年的杰出职业生涯后，他于2006年以合伙人身份退休。他现任The Greenbrier Companies,Inc.（一家为货运铁路运输市场提供设备及服务的国际供应商，于纽约证券交易所上市，股份代号：GBX）、和记港口信托（一家深水货柜码头开发商及营运商，于新加坡证券交易所上市，股份代号：NS8U）的托管人-经理Hutchison Port Holdings Management Pte.Limited及中远海运发展股份有限公司（前称‘中海集装箱运输股份有限公司’，一个主营船只及货柜租赁的综合金融服务平台，于上海证券交易所（股份代号：601866）及香港联交所（股份代号：2866）上市）的独立非执行董事。他于1973年5月在澳洲新南威尔士大学取得商学学士学位，并自1987年3月起为香港会计师公会的资深会员及自1976年9月起为澳洲及新西兰特许会计师公会的会员。于2024年12月13日获委任为长江和记实业有限公司独立非执行董事及审核委员会委员。
Graeme Jack,has been an independent non-executive director of Hutchmed (China) Limited since 2017. He is also chairman of Hutchmed (China) Limited audit committee and a member of Hutchmed (China) Limited nomination committee and remuneration committee. He has more than 40 years of experience in finance and audit. He retired as partner of PricewaterhouseCoopers in 2006 after a distinguished career with the firm for over 33 years. He is currently an independent non-executive director of The Greenbrier Companies, Inc. (an international supplier of equipment and services to the freight rail transportation markets). He was formerly a director of COSCO SHIPPING Development Co., Ltd. (formerly known as "China Shipping Container Lines Company Limited", an integrated financial services platform principally engaged in vessel and container leasing) and Hutchison Port Holdings Management Pte. Limited as the trustee-manager of Hutchison Port Holdings Trust (a developer and operator of deep water container terminals). Mr. Jack received a bachelor of commerce degree from University of New South Wales, Australia and is a fellow of the Hong Kong Institute of Certified Public Accountants and an associate of Chartered Accountants Australia and New Zealand.
胡朝红
胡朝红博士，为乐普生物科技股份有限公司的执行董事兼联席总经理、上海美雅珂（一间由胡博士于2014年创办的公司）的董事长兼总经理以及Innocube Limited的董事。胡博士于治疗性抗体、抗体药物偶联及疫苗开发领域拥有约20年的经验。在创办上海美雅珂前，胡博士于2007年6月至2013年10月担任Seagen Inc.（前称Seattle Genetics Inc.，一间纳斯达克证券交易所上市公司（股份代号：SGEN））生物分析开发及过程分析部门总监；2006年1月至2007年5月担任Glaxo Smith Kline plc（一间纽约证券交易所上市公司（股份代号：GSK））分子生物与临床免疫部门总监；1997年10月至2005年12月担任ID Biomedical Corporation（前称ID Vaccine Corporation，一间纳斯达克证券交易所上市公司（股份代号：IDBE），后于2005年退市）分子生物与临床免疫部门研究科学家及总监；1992年9月至1997年10月担任华盛顿大学博士后研究员。胡博士于1986年7月获得中国武汉大学生物化学学士学位并于1991年7月获得中国科学院生物物理研究所科学博士学位。胡博士于1995年获中国国务院授予国家自然科学奖二等奖。于2024年11月21日获委任为和黄医药（中国）有限公司独立非执行董事。于2025年2月4日获委任为和黄医药（中国）有限公司提名委员会委员。于2024年11月21日获委任为和黄医药（中国）有限公司技术委员会委员。
Chaohong HU,has been an independent non-executive director of Hutchison China Meditech Limited since November 2024. She is also a member of the nomination committee and technical committee of Hutchison China Meditech Limited. Dr. Hu has over 20 years of experience in the development of therapeutic antibodies, ADCs, and vaccines. Throughout her career, she has demonstrated strong leadership and innovative capabilities, leading various research and development initiatives. Dr. Hu's expertise spans from early-stage discovery to clinical development and commercialization. She also has a proven track record of successful business development and strategic partnerships, including out-licensing and collaboration. She is currently chief operating officer of D Biotherapeutics, LLC and an owner and principal consultant of Lakebio Consulting, LLC. She was previously executive director and co-chief executive officer of Lepu Biopharma Co., Ltd. from 2020 to 2024. She was also chief executive officer and chairman of the board of Shanghai Miracogen nc., a company founded by Dr. Hu, focusing on the research and development, clinical study and industrialization of new drugs for targeted cancer therapy – antibody drug conjugates, from 2014 to 2024. She disposed of all her interests in Shanghai Miracogen nc. in 2020. Prior to founding Shanghai Miracogen nc., Dr. Hu served as a director of the Bioassay Development and Process Analytics department at Seagen nc., director of Molecular Biology and Clinical mmunology department of GlaxoSmithKline plc (currently GSK plc), and research scientist and director of molecular biology and clinical mmunology department of D Biomedical Corporation. She was also a postdoctoral fellow of the University of Washington. Dr. Hu holds a bachelor of science degree in biochemistry from Wuhan University and a PhD in molecular biology from nstitute of Biophysics, Chinese Academy of Sciences.
胡朝红博士，为乐普生物科技股份有限公司的执行董事兼联席总经理、上海美雅珂（一间由胡博士于2014年创办的公司）的董事长兼总经理以及Innocube Limited的董事。胡博士于治疗性抗体、抗体药物偶联及疫苗开发领域拥有约20年的经验。在创办上海美雅珂前，胡博士于2007年6月至2013年10月担任Seagen Inc.（前称Seattle Genetics Inc.，一间纳斯达克证券交易所上市公司（股份代号：SGEN））生物分析开发及过程分析部门总监；2006年1月至2007年5月担任Glaxo Smith Kline plc（一间纽约证券交易所上市公司（股份代号：GSK））分子生物与临床免疫部门总监；1997年10月至2005年12月担任ID Biomedical Corporation（前称ID Vaccine Corporation，一间纳斯达克证券交易所上市公司（股份代号：IDBE），后于2005年退市）分子生物与临床免疫部门研究科学家及总监；1992年9月至1997年10月担任华盛顿大学博士后研究员。胡博士于1986年7月获得中国武汉大学生物化学学士学位并于1991年7月获得中国科学院生物物理研究所科学博士学位。胡博士于1995年获中国国务院授予国家自然科学奖二等奖。于2024年11月21日获委任为和黄医药（中国）有限公司独立非执行董事。于2025年2月4日获委任为和黄医药（中国）有限公司提名委员会委员。于2024年11月21日获委任为和黄医药（中国）有限公司技术委员会委员。
Chaohong HU,has been an independent non-executive director of Hutchison China Meditech Limited since November 2024. She is also a member of the nomination committee and technical committee of Hutchison China Meditech Limited. Dr. Hu has over 20 years of experience in the development of therapeutic antibodies, ADCs, and vaccines. Throughout her career, she has demonstrated strong leadership and innovative capabilities, leading various research and development initiatives. Dr. Hu's expertise spans from early-stage discovery to clinical development and commercialization. She also has a proven track record of successful business development and strategic partnerships, including out-licensing and collaboration. She is currently chief operating officer of D Biotherapeutics, LLC and an owner and principal consultant of Lakebio Consulting, LLC. She was previously executive director and co-chief executive officer of Lepu Biopharma Co., Ltd. from 2020 to 2024. She was also chief executive officer and chairman of the board of Shanghai Miracogen nc., a company founded by Dr. Hu, focusing on the research and development, clinical study and industrialization of new drugs for targeted cancer therapy – antibody drug conjugates, from 2014 to 2024. She disposed of all her interests in Shanghai Miracogen nc. in 2020. Prior to founding Shanghai Miracogen nc., Dr. Hu served as a director of the Bioassay Development and Process Analytics department at Seagen nc., director of Molecular Biology and Clinical mmunology department of GlaxoSmithKline plc (currently GSK plc), and research scientist and director of molecular biology and clinical mmunology department of D Biomedical Corporation. She was also a postdoctoral fellow of the University of Washington. Dr. Hu holds a bachelor of science degree in biochemistry from Wuhan University and a PhD in molecular biology from nstitute of Biophysics, Chinese Academy of Sciences.
黄德伟
黄德伟在会计、审计及企业融资方面拥有超过35年的丰富经验。他在协助公司在证券交易所上市方面发挥了关键作用，并在完成众多并购方面发挥了重要作用。在经历了三十多年的杰出职业生涯后，黄先生于2017年退休，成为普华永道会计师事务所的合伙人。黄先生，现任Melbourne Enterprises Limited（HKEX：158）非执行董事。曾任香港会计师公会（简称“香港会计师公会”）会长及理事、香港会计师公会审计准则委员会主席、国际会计师公会多个委员会成员。他也是可持续农业发展基金咨询委员会的成员。黄先生拥有新西兰奥塔哥大学商学学士学位，是香港会计师公会会员和澳大利亚和新西兰特许会计师协会协理。于2025年3月5日获委任位和黄医药（中国）有限公司独立非执行董事。于2023年5月31日获委任为万邦投资有限公司审核委员会委员。
WONG Tak Wai,has been an Independent Non-executive Director of Hutchison China Meditech Limited since March 2025. He is also a member of the Audit Committee of Hutchison China Meditech Limited. Mr. Wong has over 35 years of extensive experience in accounting, auditing and corporate finance. He has acted in a pivotal role in assisting companies with their stock exchange listings and has been instrumental in completing numerous mergers and acquisitions. After a distinguished career spanning more than three decades, Mr. Wong retired as a partner of PricewaterhouseCoopers in 2017. Mr. Wong is currently a non-executive director of Melbourne Enterprises Limited. He was the president and a council member of the HKICPA, chairman of the HKICPA auditing standards committee, and a member of various committees of the International Federation of Accountants. He was also a member of the Sustainable Agricultural Development Fund Advisory Committee. Mr. Wong holds a bachelor of commerce degree from University of Otago, New Zealand and is a fellow of the HKICPA and an associate of the CAANZ.
黄德伟在会计、审计及企业融资方面拥有超过35年的丰富经验。他在协助公司在证券交易所上市方面发挥了关键作用，并在完成众多并购方面发挥了重要作用。在经历了三十多年的杰出职业生涯后，黄先生于2017年退休，成为普华永道会计师事务所的合伙人。黄先生，现任Melbourne Enterprises Limited（HKEX：158）非执行董事。曾任香港会计师公会（简称“香港会计师公会”）会长及理事、香港会计师公会审计准则委员会主席、国际会计师公会多个委员会成员。他也是可持续农业发展基金咨询委员会的成员。黄先生拥有新西兰奥塔哥大学商学学士学位，是香港会计师公会会员和澳大利亚和新西兰特许会计师协会协理。于2025年3月5日获委任位和黄医药（中国）有限公司独立非执行董事。于2023年5月31日获委任为万邦投资有限公司审核委员会委员。
WONG Tak Wai,has been an Independent Non-executive Director of Hutchison China Meditech Limited since March 2025. He is also a member of the Audit Committee of Hutchison China Meditech Limited. Mr. Wong has over 35 years of extensive experience in accounting, auditing and corporate finance. He has acted in a pivotal role in assisting companies with their stock exchange listings and has been instrumental in completing numerous mergers and acquisitions. After a distinguished career spanning more than three decades, Mr. Wong retired as a partner of PricewaterhouseCoopers in 2017. Mr. Wong is currently a non-executive director of Melbourne Enterprises Limited. He was the president and a council member of the HKICPA, chairman of the HKICPA auditing standards committee, and a member of various committees of the International Federation of Accountants. He was also a member of the Sustainable Agricultural Development Fund Advisory Committee. Mr. Wong holds a bachelor of commerce degree from University of Otago, New Zealand and is a fellow of the HKICPA and an associate of the CAANZ.
高管简历
中英对照 |
中文 |
英文
苏慰国
苏慰国先生，博士，自2017年3月起担任和黄医药（中国）有限公司执行董事及自2012年4月起担任和黄医药（中国）有限公司执行副总裁兼首席科学官。他亦为技术委员会成员。自加入公司以来，苏博士带领进行所有药物的发现及研究，包括作为肿瘤╱免疫业务的关键领导人策划科学策略，亦负责发掘公司管线中的每一种小分子候选药物。于2005年3月加入集团前，苏博士于辉瑞公司美国研发部门工作。于2017年3月，他获中国医药创新促进会（PhIRDA）授予《最具影响力的药物研发领军人物》奖。苏博士于1982年1月在上海复旦大学取得化学理学学士学位，及在哈佛大学师从诺贝尔奖得主E.J.Corey教授，在其指导下于1988年6月取得化学博士学位并从事博士后研究。2022年3月3日担任和黄医药（中国）有限公司首席执行官。于2017年3月1日获委任为和黄医药（中国）有限公司技术委员会委员。
Weiguo SU,has been an executive director of Hutchison China Meditech Limited since 2017 and chief executive officer of Hutchison China Meditech Limited Company since 2022. He is also Hutchmed (China) Limited chief scientific officer since 2012. He is a member of Hutchmed (China) Limited technical committee. Dr. Su has headed all drug discovery and research since he joined Hutchmed (China) Limited company, including master-minding Hutchmed (China) Limited scientific strategy, being a key leader of Hutchmed (China) Limited Oncology/Immunology operations, and responsible for the discovery of each and every small molecule drug candidate in Hutchmed (China) Limited pipeline. Prior to joining Hutchmed (China) Limited in 2005, Dr. Su worked with the U.S. research and development department of Pfizer, Inc. In 2017, Dr. Su was granted the prestigious award by the China Pharmaceutical Innovation and Research Development Association (PhIRDA) as one of the Most Influential Drug R&D Leaders in China. Dr. Su received a bachelor of science degree in chemistry from Fudan University in Shanghai and completed a PhD and post-doctoral fellowship in chemistry at Harvard University under the guidance of Nobel Laureate Professor E. J. Corey.
苏慰国先生，博士，自2017年3月起担任和黄医药（中国）有限公司执行董事及自2012年4月起担任和黄医药（中国）有限公司执行副总裁兼首席科学官。他亦为技术委员会成员。自加入公司以来，苏博士带领进行所有药物的发现及研究，包括作为肿瘤╱免疫业务的关键领导人策划科学策略，亦负责发掘公司管线中的每一种小分子候选药物。于2005年3月加入集团前，苏博士于辉瑞公司美国研发部门工作。于2017年3月，他获中国医药创新促进会（PhIRDA）授予《最具影响力的药物研发领军人物》奖。苏博士于1982年1月在上海复旦大学取得化学理学学士学位，及在哈佛大学师从诺贝尔奖得主E.J.Corey教授，在其指导下于1988年6月取得化学博士学位并从事博士后研究。2022年3月3日担任和黄医药（中国）有限公司首席执行官。于2017年3月1日获委任为和黄医药（中国）有限公司技术委员会委员。
Weiguo SU,has been an executive director of Hutchison China Meditech Limited since 2017 and chief executive officer of Hutchison China Meditech Limited Company since 2022. He is also Hutchmed (China) Limited chief scientific officer since 2012. He is a member of Hutchmed (China) Limited technical committee. Dr. Su has headed all drug discovery and research since he joined Hutchmed (China) Limited company, including master-minding Hutchmed (China) Limited scientific strategy, being a key leader of Hutchmed (China) Limited Oncology/Immunology operations, and responsible for the discovery of each and every small molecule drug candidate in Hutchmed (China) Limited pipeline. Prior to joining Hutchmed (China) Limited in 2005, Dr. Su worked with the U.S. research and development department of Pfizer, Inc. In 2017, Dr. Su was granted the prestigious award by the China Pharmaceutical Innovation and Research Development Association (PhIRDA) as one of the Most Influential Drug R&D Leaders in China. Dr. Su received a bachelor of science degree in chemistry from Fudan University in Shanghai and completed a PhD and post-doctoral fellowship in chemistry at Harvard University under the guidance of Nobel Laureate Professor E. J. Corey.
李健鸿
李健鸿先生于2009年加入和记黄埔医药。自1998年起，他在美国和欧洲从事医药咨询工作。加入和记黄埔医药之前，李健鸿先生曾就职于瑞士瑞信银行，任副总裁，分别在纽约和伦敦分部工作过。期间，他参与执行并发起多个像阿斯利康、百时美施贵宝、美国健赞等生命科学领域公司的并购、上市和融资项目。在此之前，李健鸿先生曾就职于百时美施贵宝商务开发部负责项目引进。李健鸿先生以优异的成绩毕业于伦敦大学学院，并在麻省理工大学斯隆商学院获得工商管理硕士学位。2021年6月18日为和黄医药（中国）有限公司财务与发展的高级副总裁。
Mark Lee,is Hutchmed (China) Limited senior vice president of corporate management and communications. He began working in healthcare investment banking in the United States and Europe in 1998 and joined Hutchmed (China) Limited in 2009. Based in the New York and London offices of Credit Suisse, Mr. Lee was involved in the execution and origination of mergers, acquisitions, public and private financings and corporate strategy for life science companies such as AstraZeneca, Bristol-Myers Squibb and Genzyme, as well as other medical product and service companies. Mr. Lee received his bachelor's degree in biochemical engineering with first class honors from University College London, where he was awarded a Dean's Commendation. He also received a master of business administration from the Massachusetts Institute of Technology's Sloan School of Management.
李健鸿先生于2009年加入和记黄埔医药。自1998年起，他在美国和欧洲从事医药咨询工作。加入和记黄埔医药之前，李健鸿先生曾就职于瑞士瑞信银行，任副总裁，分别在纽约和伦敦分部工作过。期间，他参与执行并发起多个像阿斯利康、百时美施贵宝、美国健赞等生命科学领域公司的并购、上市和融资项目。在此之前，李健鸿先生曾就职于百时美施贵宝商务开发部负责项目引进。李健鸿先生以优异的成绩毕业于伦敦大学学院，并在麻省理工大学斯隆商学院获得工商管理硕士学位。2021年6月18日为和黄医药（中国）有限公司财务与发展的高级副总裁。
Mark Lee,is Hutchmed (China) Limited senior vice president of corporate management and communications. He began working in healthcare investment banking in the United States and Europe in 1998 and joined Hutchmed (China) Limited in 2009. Based in the New York and London offices of Credit Suisse, Mr. Lee was involved in the execution and origination of mergers, acquisitions, public and private financings and corporate strategy for life science companies such as AstraZeneca, Bristol-Myers Squibb and Genzyme, as well as other medical product and service companies. Mr. Lee received his bachelor's degree in biochemical engineering with first class honors from University College London, where he was awarded a Dean's Commendation. He also received a master of business administration from the Massachusetts Institute of Technology's Sloan School of Management.
王清梅
王清梅，2010年加入和记黄埔医药。之前，她任职美国礼来制药公司，负责礼来在中国及亚洲的生物研发。 在礼来工作的16年间，领导过数个在传染病， 炎症， 及抗肿瘤等领域的研发团队，是全球最为领先的丙肝创新药INCIVEK（telepravir）专利的共同发明人。著有50余篇文章，拥有多篇国际专利， 并担任过数个专刊和国际基金会的评委。王博士在美国的普渡大学获得博士学位。为和黄医药（中国）有限公司商务开发与战略合作高级副总裁。于2021年12月担任和黄医药（中国）有限公司高级副总裁（商务开发与战略合作）。
May Wang,is Hutchmed (China) Limited senior vice president of business development & strategic alliances. Prior to joining Hutchmed (China) Limited in 2010, Dr. Wang spent 16 years with Eli Lilly where she was the head of Eli Lilly's Asian Biology Research and responsible for establishing and managing research collaborations in China and across Asia. Dr. Wang holds numerous patents, has published more than 50 peer-reviewed articles and has given dozens of seminars and plenary lectures. Dr. Wang received a PhD in biochemistry from Purdue University.
王清梅，2010年加入和记黄埔医药。之前，她任职美国礼来制药公司，负责礼来在中国及亚洲的生物研发。 在礼来工作的16年间，领导过数个在传染病， 炎症， 及抗肿瘤等领域的研发团队，是全球最为领先的丙肝创新药INCIVEK（telepravir）专利的共同发明人。著有50余篇文章，拥有多篇国际专利， 并担任过数个专刊和国际基金会的评委。王博士在美国的普渡大学获得博士学位。为和黄医药（中国）有限公司商务开发与战略合作高级副总裁。于2021年12月担任和黄医药（中国）有限公司高级副总裁（商务开发与战略合作）。
May Wang,is Hutchmed (China) Limited senior vice president of business development & strategic alliances. Prior to joining Hutchmed (China) Limited in 2010, Dr. Wang spent 16 years with Eli Lilly where she was the head of Eli Lilly's Asian Biology Research and responsible for establishing and managing research collaborations in China and across Asia. Dr. Wang holds numerous patents, has published more than 50 peer-reviewed articles and has given dozens of seminars and plenary lectures. Dr. Wang received a PhD in biochemistry from Purdue University.
吴振平
吴振平博士于2008年加入和记黄埔医药。他在生物医药领域拥有21年的药物研发经验。吴博士曾在位于加州的药物研发公司Phenomix任药学部高级总监。在此之前，他曾担任辉瑞圣地亚哥全球研发中心（前称为Agouron 医药公司）药物开发部总监，之前在罗氏加州研发中心（Roche Palo Alto）任资深科学家。吴博士领导过多个项目的研发团队，将多个新药候选药物推进至临床各个阶段和市场，包括舒尼替尼（Sutent）——由辉瑞研发的新型具重磅炸弹潜力的抗癌药物。吴博士于香港大学获得博士学位并在加州大学尔湾分校取得了MBA学位。吴博士曾任中美生物技术和制药协会理事长和会长。2003年，他因舒尼替尼（Sutent）项目获得辉瑞杰出员工奖。他带领的索凡替尼课题组荣获2010年度和记黄埔医药优秀团队奖。于2008年4月加入公司并自2012年1月起担任和黄医药（中国）有限公司药物科学高级副总裁。
Zhenping WU,joined Hutchison China Meditech Limited in 2008 and is Hutchison China Meditech Limited executive vice president of pharmaceutical sciences and manufacturing. Dr. Wu has over 30 years of experience in drug discovery and development. His past positions include senior director of pharmaceutical sciences at Phenomix Corporation, a U.S.-based biotechnology company, director of pharmaceutical development at Pfizer Global Research & Development in California (formerly Agouron Pharmaceuticals) and a group leader at Roche at its Palo Alto site. He is a past chairman and president of the board of the Sino-American Biotechnology and Pharmaceutical Association. Dr. Wu received a PhD from the University of Hong Kong and a master in business administration from the University of California at Irvine.
吴振平博士于2008年加入和记黄埔医药。他在生物医药领域拥有21年的药物研发经验。吴博士曾在位于加州的药物研发公司Phenomix任药学部高级总监。在此之前，他曾担任辉瑞圣地亚哥全球研发中心（前称为Agouron 医药公司）药物开发部总监，之前在罗氏加州研发中心（Roche Palo Alto）任资深科学家。吴博士领导过多个项目的研发团队，将多个新药候选药物推进至临床各个阶段和市场，包括舒尼替尼（Sutent）——由辉瑞研发的新型具重磅炸弹潜力的抗癌药物。吴博士于香港大学获得博士学位并在加州大学尔湾分校取得了MBA学位。吴博士曾任中美生物技术和制药协会理事长和会长。2003年，他因舒尼替尼（Sutent）项目获得辉瑞杰出员工奖。他带领的索凡替尼课题组荣获2010年度和记黄埔医药优秀团队奖。于2008年4月加入公司并自2012年1月起担任和黄医药（中国）有限公司药物科学高级副总裁。
Zhenping WU,joined Hutchison China Meditech Limited in 2008 and is Hutchison China Meditech Limited executive vice president of pharmaceutical sciences and manufacturing. Dr. Wu has over 30 years of experience in drug discovery and development. His past positions include senior director of pharmaceutical sciences at Phenomix Corporation, a U.S.-based biotechnology company, director of pharmaceutical development at Pfizer Global Research & Development in California (formerly Agouron Pharmaceuticals) and a group leader at Roche at its Palo Alto site. He is a past chairman and president of the board of the Sino-American Biotechnology and Pharmaceutical Association. Dr. Wu received a PhD from the University of Hong Kong and a master in business administration from the University of California at Irvine.
Edith SHIH
Edith SHIH，自2006年起担任和黄医药(中国)有限公司的非执行董事，自2000年起担任和黄医药(中国)有限公司秘书及集团公司的公司秘书。她亦为和黄医药(中国)有限公司可持续发展委员会主席，并为自2006年起担任和黄医药(中国)有限公司非执行董事、自2000年起担任和黄医药(中国)有限公司秘书及集团公司秘书的成员。她亦为和黄医药(中国)有限公司可持续发展委员会主席及和黄医药（中国）有限公司薪酬委员会成员。她在法律、监管、公司财务、合规和公司治理领域拥有超过40年的经验。她也是长江和记黄埔的执行董事兼公司秘书。她自1989年起任职于长江实业（控股）有限公司（“长和”）集团，自1991年起任职于Hutchison Whampoa有限公司（“HWL”）。长和和HWL此前均在联交所上市，于2015年成为长江和记的全资附属公司。她曾在HWL集团内以各种身份行事，包括HWL的首席集团总法律顾问和公司秘书以及HWL子公司和联营公司的董事和公司秘书。Shih女士还担任和记电讯香港控股有限公司的非执行董事，Hutchison Port Holdings Management Pte. Limited担任和记港口控股信托的受托管理人和PT Duta Intidaya Tbk的专员。此外，Shih女士是和黄医药（中国）有限公司的某些主要股东（即SFO的含义）的董事，以及和黄医药（中国）有限公司的某些主要股东控制的某些公司的董事。上述公司要么是长江和记黄埔的子公司，要么是长江和记黄埔的联营公司，而Shih女士作为长江和记黄埔的董事对其进行监督。她是英国特许管治学会（“CGI”）的前任国际会长和现任理事会成员，也是香港特许管治学会（“HKCGI”）的前任会长和现任名誉顾问。此外，她还担任会计及财务报告委员会流程审查小组主席、香港科技大学理事会副主席以及香港管理协会执行委员会和理事会成员。她也是证券及期货上诉审裁处的成员。Shih女士是一名在英格兰和威尔士、香港和澳大利亚维多利亚州具有律师资格的律师，也是CGI和HKCGI的研究员，担任特许秘书和特许治理薪酬委员会。她在法律、监管、公司财务、合规和公司治理领域拥有超过40年的经验。她也是长江和记黄埔的执行董事兼公司秘书。她自1989年起任职于长江实业（控股）有限公司（“长和”）集团，自1991年起任职于Hutchison Whampoa有限公司（“HWL”）。长和和HWL此前均在联交所上市，于2015年成为长江和记的全资附属公司。她曾在HWL集团内以各种身份行事，包括HWL的首席集团总法律顾问和公司秘书以及HWL子公司和联营公司的董事和公司秘书。Shih女士还担任和记电讯香港控股有限公司的非执行董事，Hutchison Port Holdings Management Pte. Limited担任和记港口控股信托的受托管理人和PT Duta Intidaya Tbk的专员。此外，Shih女士是和黄医药（中国）有限公司的某些主要股东（即SFO所指）的董事，以及和黄医药（中国）有限公司的某些主要股东控制的某些公司的董事。上述公司要么是长江和记黄埔的子公司，要么是长江和记黄埔的联营公司，而Shih女士作为长江和记黄埔的董事对其进行监督。她是英国特许管治学会（“CGI”）的前任国际会长和现任理事会成员，也是香港特许管治学会（“HKCGI”）的前任会长和现任名誉顾问。此外，她还担任会计及财务报告委员会流程审查小组主席、香港科技大学理事会副主席，以及香港管理协会执行委员会和理事会成员。她也是证券及期货上诉审裁处的成员。Shih女士是一名在英格兰和威尔士、香港和澳大利亚维多利亚州具有律师资格的律师，也是CGI和HKCGI的研究员，拥有特许秘书和特许治理专业双重称号。她拥有菲律宾大学理学学士学位和文学硕士学位以及艺术硕士学位和教育硕士学位。
Edith SHIH,has been a non-executive director of Hutchison China Meditech Limited since 2006, the company secretary of Hutchison China Meditech Limited company and the company secretary of group companies since 2000. She is also chairman of Hutchison China Meditech Limited sustainability committee and a member of has been a non-executive director of Hutchison China Meditech Limited since 2006, the company secretary of Hutchison China Meditech Limited company and the company secretary of group companies since 2000. She is also chairman of Hutchison China Meditech Limited sustainability committee and a member of Hutchmed (China) Limited remuneration committee. She has over 40 years of experience in legal, regulatory, corporate finance, compliance and corporate governance fields. She is also executive director and company secretary of CK Hutchison. She has been with the Cheung Kong (Holdings) Limited ("CKH") group since 1989 and with Hutchison Whampoa Limited ("HWL") since 1991. Both CKH and HWL were formerly listed on SEHK and became wholly-owned subsidiaries of CK Hutchison in 2015. She has acted in various capacities within the HWL group, including head group general counsel and company secretary of HWL as well as director and company secretary of HWL subsidiaries and associated companies. Ms. Shih is in addition a non-executive director of Hutchison Telecommunications Hong Kong Holdings Limited, Hutchison Port Holdings Management Pte. Limited as the trustee-manager of Hutchison Port Holdings Trust and a commissioner of PT Duta Intidaya Tbk. In addition, Ms. Shih is a director of certain substantial shareholders (within the meaning of the SFO) of Hutchmed (China) Limited and certain companies controlled by certain substantial shareholders of Hutchmed (China) Limited The aforementioned companies are either subsidiaries or associated companies of CK Hutchison of which Ms. Shih has oversight as a director of CK Hutchison. She is a past international president and current member of the Council of The Chartered Governance Institute ("CGI") as well as a past president and current honorary advisor of The Hong Kong Chartered Governance Institute ("HKCGI"). Further, she is also chairman of the process review panel for the Accounting and Financial Reporting Council, vice-chairman of the Council of The Hong Kong University of Science and Technology, and a member of the Executive Committee and Council of The Hong Kong Management Association. She was also a member of the Securities and Futures Appeal Tribunal. Ms. Shih is a solicitor qualified in England and Wales, Hong Kong and Victoria, Australia and a fellow of both the CGI and HKCGI, holding chartered secretary and chartered governanceremuneration committee. She has over 40 years of experience in legal, regulatory, corporate finance, compliance and corporate governance fields. She is also executive director and company secretary of CK Hutchison. She has been with the Cheung Kong (Holdings) Limited ("CKH") group since 1989 and with Hutchison Whampoa Limited ("HWL") since 1991. Both CKH and HWL were formerly listed on SEHK and became wholly-owned subsidiaries of CK Hutchison in 2015. She has acted in various capacities within the HWL group, including head group general counsel and company secretary of HWL as well as director and company secretary of HWL subsidiaries and associated companies. Ms. Shih is in addition a non-executive director of Hutchison Telecommunications Hong Kong Holdings Limited, Hutchison Port Holdings Management Pte. Limited as the trustee-manager of Hutchison Port Holdings Trust and a commissioner of PT Duta Intidaya Tbk. In addition, Ms. Shih is a director of certain substantial shareholders (within the meaning of the SFO) of Hutchmed (China) Limited and certain companies controlled by certain substantial shareholders of Hutchmed (China) Limited The aforementioned companies are either subsidiaries or associated companies of CK Hutchison of which Ms. Shih has oversight as a director of CK Hutchison. She is a past international president and current member of the Council of The Chartered Governance Institute ("CGI") as well as a past president and current honorary advisor of The Hong Kong Chartered Governance Institute ("HKCGI"). Further, she is also chairman of the process review panel for the Accounting and Financial Reporting Council, vice-chairman of the Council of The Hong Kong University of Science and Technology, and a member of the Executive Committee and Council of The Hong Kong Management Association. She was also a member of the Securities and Futures Appeal Tribunal. Ms. Shih is a solicitor qualified in England and Wales, Hong Kong and Victoria, Australia and a fellow of both the CGI and HKCGI, holding chartered secretary and chartered governance professional dual designations. She holds a bachelor of science degree and a master of arts degree from the University of the Philippines as well as a master of arts degree and a master of education degree from Columbia University, New York.
Edith SHIH，自2006年起担任和黄医药(中国)有限公司的非执行董事，自2000年起担任和黄医药(中国)有限公司秘书及集团公司的公司秘书。她亦为和黄医药(中国)有限公司可持续发展委员会主席，并为自2006年起担任和黄医药(中国)有限公司非执行董事、自2000年起担任和黄医药(中国)有限公司秘书及集团公司秘书的成员。她亦为和黄医药(中国)有限公司可持续发展委员会主席及和黄医药（中国）有限公司薪酬委员会成员。她在法律、监管、公司财务、合规和公司治理领域拥有超过40年的经验。她也是长江和记黄埔的执行董事兼公司秘书。她自1989年起任职于长江实业（控股）有限公司（“长和”）集团，自1991年起任职于Hutchison Whampoa有限公司（“HWL”）。长和和HWL此前均在联交所上市，于2015年成为长江和记的全资附属公司。她曾在HWL集团内以各种身份行事，包括HWL的首席集团总法律顾问和公司秘书以及HWL子公司和联营公司的董事和公司秘书。Shih女士还担任和记电讯香港控股有限公司的非执行董事，Hutchison Port Holdings Management Pte. Limited担任和记港口控股信托的受托管理人和PT Duta Intidaya Tbk的专员。此外，Shih女士是和黄医药（中国）有限公司的某些主要股东（即SFO的含义）的董事，以及和黄医药（中国）有限公司的某些主要股东控制的某些公司的董事。上述公司要么是长江和记黄埔的子公司，要么是长江和记黄埔的联营公司，而Shih女士作为长江和记黄埔的董事对其进行监督。她是英国特许管治学会（“CGI”）的前任国际会长和现任理事会成员，也是香港特许管治学会（“HKCGI”）的前任会长和现任名誉顾问。此外，她还担任会计及财务报告委员会流程审查小组主席、香港科技大学理事会副主席以及香港管理协会执行委员会和理事会成员。她也是证券及期货上诉审裁处的成员。Shih女士是一名在英格兰和威尔士、香港和澳大利亚维多利亚州具有律师资格的律师，也是CGI和HKCGI的研究员，担任特许秘书和特许治理薪酬委员会。她在法律、监管、公司财务、合规和公司治理领域拥有超过40年的经验。她也是长江和记黄埔的执行董事兼公司秘书。她自1989年起任职于长江实业（控股）有限公司（“长和”）集团，自1991年起任职于Hutchison Whampoa有限公司（“HWL”）。长和和HWL此前均在联交所上市，于2015年成为长江和记的全资附属公司。她曾在HWL集团内以各种身份行事，包括HWL的首席集团总法律顾问和公司秘书以及HWL子公司和联营公司的董事和公司秘书。Shih女士还担任和记电讯香港控股有限公司的非执行董事，Hutchison Port Holdings Management Pte. Limited担任和记港口控股信托的受托管理人和PT Duta Intidaya Tbk的专员。此外，Shih女士是和黄医药（中国）有限公司的某些主要股东（即SFO所指）的董事，以及和黄医药（中国）有限公司的某些主要股东控制的某些公司的董事。上述公司要么是长江和记黄埔的子公司，要么是长江和记黄埔的联营公司，而Shih女士作为长江和记黄埔的董事对其进行监督。她是英国特许管治学会（“CGI”）的前任国际会长和现任理事会成员，也是香港特许管治学会（“HKCGI”）的前任会长和现任名誉顾问。此外，她还担任会计及财务报告委员会流程审查小组主席、香港科技大学理事会副主席，以及香港管理协会执行委员会和理事会成员。她也是证券及期货上诉审裁处的成员。Shih女士是一名在英格兰和威尔士、香港和澳大利亚维多利亚州具有律师资格的律师，也是CGI和HKCGI的研究员，拥有特许秘书和特许治理专业双重称号。她拥有菲律宾大学理学学士学位和文学硕士学位以及艺术硕士学位和教育硕士学位。
Edith SHIH,has been a non-executive director of Hutchison China Meditech Limited since 2006, the company secretary of Hutchison China Meditech Limited company and the company secretary of group companies since 2000. She is also chairman of Hutchison China Meditech Limited sustainability committee and a member of has been a non-executive director of Hutchison China Meditech Limited since 2006, the company secretary of Hutchison China Meditech Limited company and the company secretary of group companies since 2000. She is also chairman of Hutchison China Meditech Limited sustainability committee and a member of Hutchmed (China) Limited remuneration committee. She has over 40 years of experience in legal, regulatory, corporate finance, compliance and corporate governance fields. She is also executive director and company secretary of CK Hutchison. She has been with the Cheung Kong (Holdings) Limited ("CKH") group since 1989 and with Hutchison Whampoa Limited ("HWL") since 1991. Both CKH and HWL were formerly listed on SEHK and became wholly-owned subsidiaries of CK Hutchison in 2015. She has acted in various capacities within the HWL group, including head group general counsel and company secretary of HWL as well as director and company secretary of HWL subsidiaries and associated companies. Ms. Shih is in addition a non-executive director of Hutchison Telecommunications Hong Kong Holdings Limited, Hutchison Port Holdings Management Pte. Limited as the trustee-manager of Hutchison Port Holdings Trust and a commissioner of PT Duta Intidaya Tbk. In addition, Ms. Shih is a director of certain substantial shareholders (within the meaning of the SFO) of Hutchmed (China) Limited and certain companies controlled by certain substantial shareholders of Hutchmed (China) Limited The aforementioned companies are either subsidiaries or associated companies of CK Hutchison of which Ms. Shih has oversight as a director of CK Hutchison. She is a past international president and current member of the Council of The Chartered Governance Institute ("CGI") as well as a past president and current honorary advisor of The Hong Kong Chartered Governance Institute ("HKCGI"). Further, she is also chairman of the process review panel for the Accounting and Financial Reporting Council, vice-chairman of the Council of The Hong Kong University of Science and Technology, and a member of the Executive Committee and Council of The Hong Kong Management Association. She was also a member of the Securities and Futures Appeal Tribunal. Ms. Shih is a solicitor qualified in England and Wales, Hong Kong and Victoria, Australia and a fellow of both the CGI and HKCGI, holding chartered secretary and chartered governanceremuneration committee. She has over 40 years of experience in legal, regulatory, corporate finance, compliance and corporate governance fields. She is also executive director and company secretary of CK Hutchison. She has been with the Cheung Kong (Holdings) Limited ("CKH") group since 1989 and with Hutchison Whampoa Limited ("HWL") since 1991. Both CKH and HWL were formerly listed on SEHK and became wholly-owned subsidiaries of CK Hutchison in 2015. She has acted in various capacities within the HWL group, including head group general counsel and company secretary of HWL as well as director and company secretary of HWL subsidiaries and associated companies. Ms. Shih is in addition a non-executive director of Hutchison Telecommunications Hong Kong Holdings Limited, Hutchison Port Holdings Management Pte. Limited as the trustee-manager of Hutchison Port Holdings Trust and a commissioner of PT Duta Intidaya Tbk. In addition, Ms. Shih is a director of certain substantial shareholders (within the meaning of the SFO) of Hutchmed (China) Limited and certain companies controlled by certain substantial shareholders of Hutchmed (China) Limited The aforementioned companies are either subsidiaries or associated companies of CK Hutchison of which Ms. Shih has oversight as a director of CK Hutchison. She is a past international president and current member of the Council of The Chartered Governance Institute ("CGI") as well as a past president and current honorary advisor of The Hong Kong Chartered Governance Institute ("HKCGI"). Further, she is also chairman of the process review panel for the Accounting and Financial Reporting Council, vice-chairman of the Council of The Hong Kong University of Science and Technology, and a member of the Executive Committee and Council of The Hong Kong Management Association. She was also a member of the Securities and Futures Appeal Tribunal. Ms. Shih is a solicitor qualified in England and Wales, Hong Kong and Victoria, Australia and a fellow of both the CGI and HKCGI, holding chartered secretary and chartered governance professional dual designations. She holds a bachelor of science degree and a master of arts degree from the University of the Philippines as well as a master of arts degree and a master of education degree from Columbia University, New York.
Michael Ming SHI
Michael Ming SHI是和黄医药（中国）有限公司执行副总裁、研发主管兼首席医疗官，负责和黄医药（中国）有限公司从战略到执行的药物发现和开发。在2022年加入和黄医药（中国）有限公司之前，SHI博士是Transcenta Holding Limited的全球研发主管和首席医疗官，帮助在中国和美国建立了一个强大的全球研发机构，并推进了七个项目的临床开发和多个临床前候选项目的提名。在那之前，SHI博士在Novartis工作了超过15年，担任过多个高级领导职位，包括临床开发的全球项目临床主管。从临床概念验证到成功执行全球关键试验、产品注册和生命周期管理，他在多个新型肿瘤/血液学产品的临床开发中发挥了关键的领导作用。SHI博士是美国临床肿瘤学会、欧洲临床肿瘤学会、美国血液学学会、美国癌症研究协会、中美药学会会员，以及美中抗癌协会（USCACA）执行委员会成员。SHI博士还曾在国立卫生研究院（National Institution of Health，简称“NIH”）担任遗传学变异项目主任，由国立卫生研究院院长Francis Collins博士直接指导，并在密歇根大学医学院担任兼职助理教授。SHI博士拥有南加州大学分子药理学和毒理学博士学位，并在哈佛医学院从事博士后研究。他在北京协和医学院接受医学教育。
Michael Ming SHI,is Hutchison China Meditech Limited executive vice president, head of R&D and chief medical officer. He oversees the drug discovery and development of Hutchison China Meditech Limited from strategy to execution. Prior to joining Hutchison China Meditech Limited in 2022, Dr. Shi was the global head of R&D and chief medical officer at Transcenta Holding Limited. Before that, he worked at Novartis for over 15 years, where he held various senior leadership positions including global program clinical head in clinical development. Dr. Shi is a member of American Society of Clinical Oncology, European Society of Medical Oncology, American Society of Hematology, American Association for Cancer Research, Sino-American Pharmaceutical Professionals Association and an executive committee member of the U.S.-China Anti-cancer Association ("USCACA"). Dr. Shi also worked as the program director of Genetics Variation at National Institution of Health and was an adjunct assistant professor at the University of Michigan Medical School. Dr. Shi holds a PhD in Molecular Pharmacology and Toxicology from the University of Southern California, and conducted postdoctoral research at the Harvard Medical School. He received his medical education from Peking Union Medical College.
Michael Ming SHI是和黄医药（中国）有限公司执行副总裁、研发主管兼首席医疗官，负责和黄医药（中国）有限公司从战略到执行的药物发现和开发。在2022年加入和黄医药（中国）有限公司之前，SHI博士是Transcenta Holding Limited的全球研发主管和首席医疗官，帮助在中国和美国建立了一个强大的全球研发机构，并推进了七个项目的临床开发和多个临床前候选项目的提名。在那之前，SHI博士在Novartis工作了超过15年，担任过多个高级领导职位，包括临床开发的全球项目临床主管。从临床概念验证到成功执行全球关键试验、产品注册和生命周期管理，他在多个新型肿瘤/血液学产品的临床开发中发挥了关键的领导作用。SHI博士是美国临床肿瘤学会、欧洲临床肿瘤学会、美国血液学学会、美国癌症研究协会、中美药学会会员，以及美中抗癌协会（USCACA）执行委员会成员。SHI博士还曾在国立卫生研究院（National Institution of Health，简称“NIH”）担任遗传学变异项目主任，由国立卫生研究院院长Francis Collins博士直接指导，并在密歇根大学医学院担任兼职助理教授。SHI博士拥有南加州大学分子药理学和毒理学博士学位，并在哈佛医学院从事博士后研究。他在北京协和医学院接受医学教育。
Michael Ming SHI,is Hutchison China Meditech Limited executive vice president, head of R&D and chief medical officer. He oversees the drug discovery and development of Hutchison China Meditech Limited from strategy to execution. Prior to joining Hutchison China Meditech Limited in 2022, Dr. Shi was the global head of R&D and chief medical officer at Transcenta Holding Limited. Before that, he worked at Novartis for over 15 years, where he held various senior leadership positions including global program clinical head in clinical development. Dr. Shi is a member of American Society of Clinical Oncology, European Society of Medical Oncology, American Society of Hematology, American Association for Cancer Research, Sino-American Pharmaceutical Professionals Association and an executive committee member of the U.S.-China Anti-cancer Association ("USCACA"). Dr. Shi also worked as the program director of Genetics Variation at National Institution of Health and was an adjunct assistant professor at the University of Michigan Medical School. Dr. Shi holds a PhD in Molecular Pharmacology and Toxicology from the University of Southern California, and conducted postdoctoral research at the Harvard Medical School. He received his medical education from Peking Union Medical College.
CHENG Chig Fung, Johnny
CHENG Chig Fung, Johnny，自2011年起担任和黄医药(中国)有限公司执行董事，自2008年起担任和黄医药(中国)有限公司首席财务官。他是和黄医药(中国)有限公司可持续发展委员会成员。在加入和黄医药(中国)有限公司之前，CHENG先生曾任百时美施贵宝中国财务副总裁，并于2006年末至2008年期间担任Sino-American Shanghai Squibb Pharmaceuticals Ltd.和上海Bristol-Myers Squibb （China） Investment Co. Ltd. 的董事。CHENG先生的职业生涯始于澳大利亚普华永道会计师事务所（现为普华永道会计师事务所）的审计师，随后在北京毕马威会计师事务所任职，之后在雀巢中国工作了八年，在那里他负责多个财务和控制职能部门的各种业务。CHENG先生获得阿德莱德大学会计学专业经济学学士学位，并且是澳大利亚和新西兰特许会计师事务所（“CAANZ”）的合伙人。
CHENG Chig Fung, Johnny,has been an executive director of Hutchison China Meditech Limited since 2011 and Hutchmed (China) Limited chief financial officer since 2008. He is a member of Hutchison China Meditech Limited sustainability committee. Prior to joining Hutchmed (China) Limited company, Mr. Cheng was vice president, finance of Bristol Myers Squibb in China and was a director of Sino-American Shanghai Squibb Pharmaceuticals Ltd. and Bristol-Myers Squibb (China) Investment Co. Ltd. in Shanghai between late 2006 and 2008. Mr. Cheng started his career as an auditor with Price Waterhouse (currently PricewaterhouseCoopers) in Australia and then KPMG in Beijing before spending eight years with Nestlé China where he was in charge of a number of finance and control functions in various operations. Mr. Cheng received a bachelor of economics, accounting major from the University of Adelaide and is an associate of Chartered Accountants Australia and New Zealand ("CAANZ").
CHENG Chig Fung, Johnny，自2011年起担任和黄医药(中国)有限公司执行董事，自2008年起担任和黄医药(中国)有限公司首席财务官。他是和黄医药(中国)有限公司可持续发展委员会成员。在加入和黄医药(中国)有限公司之前，CHENG先生曾任百时美施贵宝中国财务副总裁，并于2006年末至2008年期间担任Sino-American Shanghai Squibb Pharmaceuticals Ltd.和上海Bristol-Myers Squibb （China） Investment Co. Ltd. 的董事。CHENG先生的职业生涯始于澳大利亚普华永道会计师事务所（现为普华永道会计师事务所）的审计师，随后在北京毕马威会计师事务所任职，之后在雀巢中国工作了八年，在那里他负责多个财务和控制职能部门的各种业务。CHENG先生获得阿德莱德大学会计学专业经济学学士学位，并且是澳大利亚和新西兰特许会计师事务所（“CAANZ”）的合伙人。
CHENG Chig Fung, Johnny,has been an executive director of Hutchison China Meditech Limited since 2011 and Hutchmed (China) Limited chief financial officer since 2008. He is a member of Hutchison China Meditech Limited sustainability committee. Prior to joining Hutchmed (China) Limited company, Mr. Cheng was vice president, finance of Bristol Myers Squibb in China and was a director of Sino-American Shanghai Squibb Pharmaceuticals Ltd. and Bristol-Myers Squibb (China) Investment Co. Ltd. in Shanghai between late 2006 and 2008. Mr. Cheng started his career as an auditor with Price Waterhouse (currently PricewaterhouseCoopers) in Australia and then KPMG in Beijing before spending eight years with Nestlé China where he was in charge of a number of finance and control functions in various operations. Mr. Cheng received a bachelor of economics, accounting major from the University of Adelaide and is an associate of Chartered Accountants Australia and New Zealand ("CAANZ").
力仕新
力仕新先生，自2015年5月起担任和黄医药（中国）有限公司集团总法律顾问，并自2006年起便开始于公司任职。在加入公司之前，力仕新先生曾于香港和伦敦担任和记黄埔有限公司（先前为香港上市公司，重组之后，为长江和记实业有限公司的附属公司）的集团高级法律顾问，在此之前他曾任英国3电讯（Three UK，为流动电话营运商）的高级法律顾问。力仕新先生自2001年以来一直在长江和记集团工作。力仕新先生拥有英国米德尔塞克斯大学法学学士（荣誉）学位，为英格兰及威尔士执业事务律师，拥有30年的经验。于2015年05月担任和黄医药（中国）有限公司集团总法律顾问。
Charles George Rupert NIXON,has been Hutchison China Meditech Limited group general counsel since 2015 and has worked with Hutchison China Meditech Limited since 2006. Prior to joining Hutchison China Meditech Limited, Mr. Nixon was group senior legal counsel for HWL (previously a listed company in Hong Kong and after a restructuring, a subsidiary of CK Hutchison) in both Hong Kong and London and prior to that senior legal counsel for Three UK, the mobile phone operator. Mr. Nixon has been with the CK Hutchison Group since 2001. Mr. Nixon received an LL.B (Hons) from Middlesex University and is a qualified solicitor in England & Wales with over 30 years of experience.
力仕新先生，自2015年5月起担任和黄医药（中国）有限公司集团总法律顾问，并自2006年起便开始于公司任职。在加入公司之前，力仕新先生曾于香港和伦敦担任和记黄埔有限公司（先前为香港上市公司，重组之后，为长江和记实业有限公司的附属公司）的集团高级法律顾问，在此之前他曾任英国3电讯（Three UK，为流动电话营运商）的高级法律顾问。力仕新先生自2001年以来一直在长江和记集团工作。力仕新先生拥有英国米德尔塞克斯大学法学学士（荣誉）学位，为英格兰及威尔士执业事务律师，拥有30年的经验。于2015年05月担任和黄医药（中国）有限公司集团总法律顾问。
Charles George Rupert NIXON,has been Hutchison China Meditech Limited group general counsel since 2015 and has worked with Hutchison China Meditech Limited since 2006. Prior to joining Hutchison China Meditech Limited, Mr. Nixon was group senior legal counsel for HWL (previously a listed company in Hong Kong and after a restructuring, a subsidiary of CK Hutchison) in both Hong Kong and London and prior to that senior legal counsel for Three UK, the mobile phone operator. Mr. Nixon has been with the CK Hutchison Group since 2001. Mr. Nixon received an LL.B (Hons) from Middlesex University and is a qualified solicitor in England & Wales with over 30 years of experience.
(责任编辑：)
|
